San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Ionetix is raising $42,988,663.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kevin Cameron played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ionetix

Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. We are changing the paradigm when it comes to access to one of the most accurate PET imaging agents for the detection of coronary artery disease, N-13 Ammonia. Until now, this tracer was only available to a select group of institutions due to its very short half-life and the need for a large and expensive cyclotron on site. Ionetix can now provide virtually any hospital or private center with on demand N-13 Ammonia doses without the need to purchase a cyclotron.

To learn more about Ionetix, visit http://www.ionetix.com/

Contact:
Kevin Cameron, Chief Executive Officer
415-944-1440
kcameron@ionetix.com
https://www.linkedin.com/in/kevin-cameron-10424a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved